Lower-dose radiation for early-stage NK/T-cell lymphoma after chemotherapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether patients with a specific type of blood cancer (NK/T-cell lymphoma) in the nose or sinuses who have responded well to chemotherapy can be safely treated with reduced radiation doses instead of standard high-dose radiation. The goal is to reduce side effects while maintaining effective treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with nasal-type NK/T-cell lymphoma (a rare blood cancer affecting the nose or sinuses)
- Your cancer is stage I or II (early stage, not yet spread far)
- You completed chemotherapy with an asparaginase-based regimen and achieved complete remission (no visible cancer remaining)
- You have 0 or 1 risk factor (such as age over 60, certain blood test results, or stage II disease)
- Your blood counts and organ function (liver, kidneys) are normal or near-normal
- You are 18–75 years old and in good enough health to tolerate treatment (ECOG score 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
This trial tests a treatment plan for early-stage NK/T-cell lymphoma of the nose or throat. The treatment is adjusted based on how well the disease responds, aiming to be more effective and reduce side effects.
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
This trial tests whether a lower dose of radiation is just as effective as the standard dose for people with early-stage nasopharyngeal cancer, and aims to reduce side effects while keeping the cancer under control.
This trial tests if giving less radiation than usual is safe and effective for certain head and neck cancers after initial treatment with chemotherapy and immunotherapy. It aims to reduce side effects while still controlling the cancer.
This trial tests whether combining chemotherapy with radiation therapy can work well for people with early-stage NK/T-cell lymphoma that started in the nose or throat. It aims to find a more effective treatment approach with fewer side effects.
Hear when a new Lymphoma (Non-Hodgkin's Lymphoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.